ESR1 and breast cancer: Triple-negative BC, which is characterized by the absence of ER, PR, and HER2, is a most aggressive subtype and, diagnosed in younger women, has the highest mortality rate among all BCs due to a lack of effective targeted therapeutics and low response rates for chemotherapeutics [6].